Cancer Immunotherapy with CDK7 Inhibitors

Giulia Petroni; Lorenzo Galluzzi

doi:10.1016/j.trecan.2020.02.005

Cancer Immunotherapy with CDK7 Inhibitors

Giulia Petroni, Lorenzo Galluzzi

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.

Original language	English
Pages (from-to)	361-363
Number of pages	3
Journal	Trends in Cancer
Volume	6
Issue number	5
DOIs	https://doi.org/10.1016/j.trecan.2020.02.005
State	Published - May 2020
Externally published	Yes

Keywords

immune checkpoint blockade
micronuclei
PD-1
small cell lung cancer
type I interferon
YKL-5-124

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2020.02.005

Cite this

@article{58bfa519b9f34cfe9eb8379308cec03e,

title = "Cancer Immunotherapy with CDK7 Inhibitors",

abstract = "Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.",

keywords = "immune checkpoint blockade, micronuclei, PD-1, small cell lung cancer, type I interferon, YKL-5-124",

author = "Giulia Petroni and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = may,

doi = "10.1016/j.trecan.2020.02.005",

language = "English",

volume = "6",

pages = "361--363",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Cancer Immunotherapy with CDK7 Inhibitors

AU - Petroni, Giulia

AU - Galluzzi, Lorenzo

PY - 2020/5

Y1 - 2020/5

N2 - Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.

AB - Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.

KW - immune checkpoint blockade

KW - micronuclei

KW - PD-1

KW - small cell lung cancer

KW - type I interferon

KW - YKL-5-124

UR - http://www.scopus.com/inward/record.url?scp=85080095192&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2020.02.005

DO - 10.1016/j.trecan.2020.02.005

M3 - Short survey

C2 - 32348731

AN - SCOPUS:85080095192

SN - 2405-8033

VL - 6

SP - 361

EP - 363

JO - Trends in Cancer

JF - Trends in Cancer

IS - 5

ER -

Cancer Immunotherapy with CDK7 Inhibitors

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this